Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 25
Filtrar
Mais filtros

Tipo de documento
Intervalo de ano de publicação
1.
Vet Ophthalmol ; 23(4): 632-639, 2020 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-32386123

RESUMO

OBJECTIVE: To assess the clinical safety and efficacy of adjunctive therapy using Vizoovet to ameliorate clinical signs of keratoconjunctivitis sicca (KCS) in dogs. ANIMALS STUDIED: Twenty client-owned dogs. PROCEDURES: Canine patients diagnosed with KCS were enrolled in this prospective study. Patients were randomly selected to receive either Vizoovet or GenTeal drops twice daily in addition to twice daily tacrolimus 0.03% solution. Data were collected from only one eye of each patient and included STT-1, IOP, TFBUT, and results of objective clinical scoring performed by pet owners. Statistical significance was set at P ≤ .05. RESULTS: In all, 20 dogs (20 eyes) were enrolled in this prospective randomized study. Females (n = 12; 60%) outnumbered males (n = 8; 40%) and all dogs were spayed/neutered. Mean age of all dogs was 10.6 ± 3.79 years. In both treatment groups, the improvement in STT-1 values over the course of the study was significant (P = .002). When comparing the STT-1 improvements between groups, no significance was found (P = .78). In both groups, the improvement in TFBUT was significant (P = .0018). When comparing the TFBUT improvements between groups, no significance was found (P = .14). Squinting, rubbing, ocular discharge, and medication administration scores all significantly improved throughout the course of the study; however, they did not differ significantly between groups. Throughout the study, no adverse side effects were noted clinically or by the pet owner in either group. CONCLUSIONS AND CLINICAL RELEVANCE: Adjunctive treatment with Vizoovet was as safe and effective as GenTeal drops at improving clinical signs of dry eye in dogs.


Assuntos
Doenças do Cão/tratamento farmacológico , Imunossupressores/uso terapêutico , Ceratoconjuntivite Seca/veterinária , Soluções Oftálmicas/uso terapêutico , Tacrolimo/uso terapêutico , Animais , Doenças do Cão/patologia , Cães , Quimioterapia Combinada , Feminino , Imunossupressores/administração & dosagem , Ceratoconjuntivite Seca/tratamento farmacológico , Masculino , Soluções Oftálmicas/administração & dosagem , Linhagem , Projetos Piloto , Estudos Prospectivos , Tacrolimo/administração & dosagem , Resultado do Tratamento
2.
Molecules ; 24(3)2019 Feb 12.
Artigo em Inglês | MEDLINE | ID: mdl-30759852

RESUMO

Exposure to particulate matter is a risk factor for various ocular surface diseases, including keratoconjunctivitis sicca (KCS). In this study, we investigated the protective effects of apricot kernel extract (AKE) and its bioactive compound, amygdalin, on KCS induced by exposure to urban particulate matter (UPM). In the in vivo experiments, eye drops containing 0.5 mg/mL AKE (AKE-0.5) or 1 mg/mL AKE (AKE-1) were administered directly into the eyes of female rats after UPM exposure. Additionally, the effect of AKE and amygdalin on matrix metalloproteinases (MMPs) activity and the expressions of inflammatory factors, including tumor necrosis factor (TNF)-α and interleukin (IL)-6, was investigated in conjunctival epithelial cells in vitro. Topical administration of AKE-1 attenuated UPM exposure-induced reduction of tear secretion. Both AKE-0.5 and AKE-1 inhibited UPM exposure-induced corneal epithelial damage and irregularity. AKE also protected against UPM exposure-induced disruption of the mucin-4 layer on the ocular surface. In addition, AKE and amygdalin prevented UPM-induced activation of MMPs and upregulation of TNF-α and IL-6 in conjunctival epithelial cells. Therefore, AKE may have protective effects against UPM exposure-induced KCS via the inhibition of MMPs and inflammation. The pharmacological activities of AKE may be in part due to its bioactive compound, amygdalin.


Assuntos
Amigdalina/farmacologia , Ceratoconjuntivite Seca/tratamento farmacológico , Material Particulado/farmacologia , Extratos Vegetais/farmacologia , Prunus armeniaca/química , Animais , Síndromes do Olho Seco/tratamento farmacológico , Síndromes do Olho Seco/metabolismo , Células Epiteliais/efeitos dos fármacos , Células Epiteliais/metabolismo , Epitélio Corneano/efeitos dos fármacos , Epitélio Corneano/metabolismo , Feminino , Inflamação/tratamento farmacológico , Inflamação/metabolismo , Interleucina-6/metabolismo , Ceratoconjuntivite Seca/metabolismo , Metaloproteinases da Matriz/metabolismo , Mucina-4/metabolismo , Soluções Oftálmicas/farmacologia , Ratos , Ratos Sprague-Dawley , Fator de Necrose Tumoral alfa/metabolismo
3.
Arq. bras. oftalmol ; 81(5): 421-428, Sept.-Oct. 2018. tab, graf
Artigo em Inglês | LILACS | ID: biblio-950481

RESUMO

ABSTRACT Purpose: To compare the efficacy of 0.03% to­pical tacrolimus in combination with oral omega (ω) 3 with different ratios of eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), and antioxidants as adjuvant in the treatment of keratoconjunctivitis sicca (KCS) in dogs. Methods: Forty-five dogs with KCS were evaluated monthly for 6 months. Evaluations included performance of the Schirmer tear, fluorescein, and lissamine green tests. Tear film break-up time (TBUT) was assessed. Conjunctival cytology was evaluated at the beginning, middle, and end of the study. Conjunctiva was biopsied at the beginning and end of the study. Dogs were randomly assigned to one of the three groups (n=15): Group T (topical tacrolimus 0.03%), Group TO (topical tacrolimus + ω-1.5 EPA: 1 DHA), or Group TOA (topical tacrolimus + ω-1 EPA:4.5 DHA + antioxidants). Results: There was a significant improvement in clinical signs in all groups. TBUT increased throughout treatment in all groups; this effect was most pronounced in Group TO. Cytological analysis performed at the end of the study period, showed decreased levels of lymphocytes, neutrophils, and metaplastic and squamous cells in Groups T, TO, and TOA. Histological analysis performed at the end of the study period showed decreased levels of lymphocytes and neutrophils and increased levels of goblet cells. These effects were most pronounced in Group TO. Conclusion: Oral treatment with ω-3 containing a higher proportion of EPA than DHA increased the effectiveness of topical tacrolimus 0.03% in the treatment of keratoconjunctivitis sicca in dogs.


RESUMO Objetivo: Comparar a eficácia do tacrolimus 0,03% tópico associado ao ômega 3 oral, com diferentes proporções de ácido eicosapentaenoico (EPA), ácidos docosa-hexaenoicos (DHA) e antioxidantes, como adjuvante no tratamento de cães acometidos por ceratoconjuntivite seca. Métodos: Quarenta e cinco cães atendidos no Hospital Veterinário da UNOESTE portadores de ceratoconjuntivite seca foram avaliados mensalmente por 6 meses pelo Teste Lacrimal de Schirmer, Teste de Fluoresceína, Tempo de Ruptura do Filme Lacrimal, Teste de Rosa Bengala, citologia da conjuntiva no início, meio e fim do projeto e biopsia da conjuntiva no início e final do projeto. Os cães foram distribuídos aleatoriamente em 3 grupos (n=15): grupo T (tacrolimus 0,03% tópico), grupo TO (tacrolimus + ômegas 1.5 EPA/1 DHA oral) e grupo TOA (tacrolimus + ômegas 1 EPA/4,5 DHA + antioxidantes oral). Resultados: Houve uma melhora significativa nos sinais clínicos em ambos os grupos. No tempo de ruptura do filme lacrimal todos os grupos apresentaram aumento no decorrer do tratamento, sendo que o grupo TO foi o que apresentou melhor resultado em todos momentos quando comparado aos demais grupos. Ao final do experimento, os grupos T, TO e TOA apresentaram na análise citológica, diminuição de linfócitos, neutrófilos, células metaplásicas e escamosas, e na análise histopatológica, diminuição de linfócitos e neutrófilos e aumento das células caliciformes, com o grupo TO com melhor desempenho. Conclusão: O tratamento oral com ω-3 contendo uma maior proporção de EPA do que o DHA aumentou a eficácia do tacrolimus tópico 0,03% no tratamento de ceratoconjuntivite sicca em cães.


Assuntos
Animais , Cães , Ácido Eicosapentaenoico/administração & dosagem , Ácidos Docosa-Hexaenoicos/administração & dosagem , Ceratoconjuntivite Seca/veterinária , Tacrolimo/administração & dosagem , Doenças do Cão/tratamento farmacológico , Antioxidantes/administração & dosagem , Fatores de Tempo , Ceratoconjuntivite Seca/tratamento farmacológico , Administração Tópica , Resultado do Tratamento , Quimioterapia Adjuvante
4.
Arq Bras Oftalmol ; 81(5): 421-428, 2018.
Artigo em Inglês | MEDLINE | ID: mdl-30208145

RESUMO

PURPOSE: To compare the efficacy of 0.03% to-pical tacrolimus in combination with oral omega (ω) 3 with different ratios of eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), and antioxidants as adjuvant in the treatment of keratoconjunctivitis sicca (KCS) in dogs. METHODS: Forty-five dogs with KCS were evaluated monthly for 6 months. Evaluations included performance of the Schirmer tear, fluorescein, and lissamine green tests. Tear film break-up time (TBUT) was assessed. Conjunctival cytology was evaluated at the beginning, middle, and end of the study. Conjunctiva was biopsied at the beginning and end of the study. Dogs were randomly assigned to one of the three groups (n=15): Group T (topical tacrolimus 0.03%), Group TO (topical tacrolimus + ω-1.5 EPA: 1 DHA), or Group TOA (topical tacrolimus + ω-1 EPA:4.5 DHA + antioxidants). RESULTS: There was a significant improvement in clinical signs in all groups. TBUT increased throughout treatment in all groups; this effect was most pronounced in Group TO. Cytological analysis performed at the end of the study period, showed decreased levels of lymphocytes, neutrophils, and metaplastic and squamous cells in Groups T, TO, and TOA. Histological analysis performed at the end of the study period showed decreased levels of lymphocytes and neutrophils and increased levels of goblet cells. These effects were most pronounced in Group TO. CONCLUSION: Oral treatment with ω-3 containing a higher proportion of EPA than DHA increased the effectiveness of topical tacrolimus 0.03% in the treatment of keratoconjunctivitis sicca in dogs.


Assuntos
Antioxidantes/administração & dosagem , Ácidos Docosa-Hexaenoicos/administração & dosagem , Doenças do Cão/tratamento farmacológico , Ácido Eicosapentaenoico/administração & dosagem , Ceratoconjuntivite Seca/veterinária , Tacrolimo/administração & dosagem , Administração Tópica , Animais , Quimioterapia Adjuvante , Cães , Ceratoconjuntivite Seca/tratamento farmacológico , Fatores de Tempo , Resultado do Tratamento
5.
Arq. bras. oftalmol ; 81(4): 293-301, July-Aug. 2018. tab, graf
Artigo em Inglês | LILACS | ID: biblio-950477

RESUMO

ABSTRACT Objective: To compare the efficacy of 0.03% tacrolimus eye drops diluted in two different vehicles (linseed oil and olive oil) for the treatment of keratoconjunctivitis sicca (KCS) in dogs. Methods: This study included 60 dogs. Of this group, 20 were healthy and allocated to the control group, and 40 were diagnosed with bilateral KCS and randomly allocated to either the TO (tacrolimus in olive oil) or the TL (tacrolimus in linseed oil) groups. Ophthalmic examinations, Schirmer Tear Test-1 (STT-1), Tear Film Break-up Time (TBUT) and Fluorescein Test (FT) were carried out monthly, along with cytological and histopathological examinations at the beginning and end of the study. Results: The clinical signs, corneal ulcers, Schirmer Tear Test-1 values, and Tear Film Break-up Time values improved in both groups after one month of treatment. Cytological examination at the end of the study showed decreased lymphocytes, neutrophil, metaplastic, and squamous cell counts in both groups, while the histopathological analysis showed decreases in lymphocytes and neutrophils and an increase in goblet cell density (cells/mm2). The decreases in neutrophil count were more significant (p<0.05) in the TL group for both types of examination. Conclusion: In sum, 0.03% tacrolimus eye drops diluted in olive oil and linseed oil were effective in the treatment of keratoconjunctivitis sicca. None of the evaluated parameters differed significantly between the two groups, except for neutrophil count which was significantly lower in the TL group. Thus, linseed oil may be considered as an alternative diluent for tacrolimus eye drops.


RESUMO Objetivo: Comparar a eficácia do tacrolimus 0,03% colírio, diluído em óleo de linhaça e óleo de oliva, no tratamento de ceratoconjuntivite seca em cães. Métodos: Foram utilizados 60 cães; 20 cães saudáveis como grupo controle, e 40 cães com diagnóstico de ceratoconjuntivite seca bilateral, distribuídos aleatoriamente em dois grupos: Tacrolimus em óleo de oliva (TO) e Tacrolimus em óleo de semente de linhaça (TL). Os animais foram avaliados mensalmente com exames oftálmicos, Teste lacrimal de Schirmer-1 (TLS-1), Tempo de ruptura do filme lacrimal (TRFL) e Teste de Fluoresceína (TF), e mensalmente com citologia conjuntival e com exame histopatológico no início e final do estudo. Resultados: Nos dois grupos de tratamento os sinais clínicos, Teste lacrimal de Schirmer-1, óleo de semente de linhaça e Tempo de ruptura do filme lacrimal apresentaram melhora após um mês de tratamento. E no final do estudo, na análise citológica, ambos apresentaram diminuição de linfócitos, neutrófilos, células metaplásicas e células escamosas, e na análise histopatológica houve diminuição de linfócitos, neutrófilos e o aumento de células caliciformes. No grupo óleo de semente de linhaça, a diminuição de neutrófilos foi mais significativa (p<0,05) em ambas análises. Conclusão: Em suma, tacrolimus 0,03% colírio diluído em óleo de oliva e óleo de linhaça foram eficientes no tratamento de ceratoconjuntivite seca. Nenhum dos parâmetros avaliados diferiu significativamente entre os dois grupos, exceto a contagem de neutrófilos, que foi significativamente menor no grupo TL. Assim, o óleo de linhaça pode ser considerado como um diluente alternativo para o colírio tacrolimus.


Assuntos
Animais , Masculino , Feminino , Óleo de Semente do Linho/administração & dosagem , Ceratoconjuntivite Seca/veterinária , Tacrolimo/administração & dosagem , Azeite de Oliva/administração & dosagem , Imunossupressores/administração & dosagem , Ceratoconjuntivite Seca/tratamento farmacológico , Resultado do Tratamento , Quimioterapia Combinada/veterinária , Administração Oftálmica/veterinária
6.
Arq Bras Oftalmol ; 81(4): 293-301, 2018.
Artigo em Inglês | MEDLINE | ID: mdl-29995121

RESUMO

OBJECTIVE: To compare the efficacy of 0.03% tacrolimus eye drops diluted in two different vehicles (linseed oil and olive oil) for the treatment of keratoconjunctivitis sicca (KCS) in dogs. METHODS: This study included 60 dogs. Of this group, 20 were healthy and allocated to the control group, and 40 were diagnosed with bilateral KCS and randomly allocated to either the TO (tacrolimus in olive oil) or the TL (tacrolimus in linseed oil) groups. Ophthalmic examinations, Schirmer Tear Test-1 (STT-1), Tear Film Break-up Time (TBUT) and Fluorescein Test (FT) were carried out monthly, along with cytological and histopathological examinations at the beginning and end of the study. RESULTS: The clinical signs, corneal ulcers, Schirmer Tear Test-1 values, and Tear Film Break-up Time values improved in both groups after one month of treatment. Cytological examination at the end of the study showed decreased lymphocytes, neutrophil, metaplastic, and squamous cell counts in both groups, while the histopathological analysis showed decreases in lymphocytes and neutrophils and an increase in goblet cell density (cells/mm2). The decreases in neutrophil count were more significant (p<0.05) in the TL group for both types of examination. CONCLUSION: In sum, 0.03% tacrolimus eye drops diluted in olive oil and linseed oil were effective in the treatment of keratoconjunctivitis sicca. None of the evaluated parameters differed significantly between the two groups, except for neutrophil count which was significantly lower in the TL group. Thus, linseed oil may be considered as an alternative diluent for tacrolimus eye drops.


Assuntos
Imunossupressores/administração & dosagem , Ceratoconjuntivite Seca/veterinária , Óleo de Semente do Linho/administração & dosagem , Azeite de Oliva/administração & dosagem , Tacrolimo/administração & dosagem , Administração Oftálmica/veterinária , Animais , Cães , Quimioterapia Combinada/veterinária , Feminino , Ceratoconjuntivite Seca/tratamento farmacológico , Masculino , Resultado do Tratamento
7.
J Med Econ ; 21(8): 733-744, 2018 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-29781353

RESUMO

AIM: We review clinical evidence of therapeutic efficacy and effectiveness of omega-3 fatty acids (omega-3s) in keratoconjunctivitis sicca, colloquially known as dry eye disease. In doing so, we identify relevant literature to address the following questions: (1) What definitive guidance can clinical evidence offer eye physicians and their patients? (2) What aspects of omega-3 supplementation lack definitive evidence, and how might economic assessments help? METHODS: A targeted and systematic search strategy based on PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) was designed in this study for refereed clinical trials of omega-3s in dry eye treatment. Four key databases were accessed. Records were filtered through a three-step process using predetermined inclusion criteria. Data was extracted for experimental design, sample population characteristics, content of test and control groups, symptoms and associated opthalmologic conditions, diagnostic measures, patient health outcomes, adverse events, and model time horizon. RESULTS: A total of 219 records were initially identified, of which 21 prospective clinical trials, with a total of 2,973 participants, were admitted for review. Clinical evidence indicates that daily oral supplementation with omega-3s statistically correlates with dry eye treatment in the general symptomatic population as well as induced sub-populations. Reported adverse events are minimal. These trials nonetheless exhibit considerable heterogeneity in clinical endpoints, particularly as a result of the multi-factorial character of dry eye as well as continuous advances in scientific knowledge and technology. Their findings and recommendations appear to be of limited external validity. And causal inferences are needed, but difficult to establish. These have encouraged and sustained wide variations in ophthalmologic practice and normative decision-making. CONCLUSIONS: Comparability of omega-3 therapeutic efficacy and effectiveness remains a major challenge in dry eye disease management. Notwithstanding its multi-factorial character, addressing prevailing methodological and empirical issues in clinical trials will help reduce knowledge gaps and normative choices among eye physicians and patients alike. In this regard, pharmacoeconomics offers a useful and robust toolset through which analysis of cost-minimization, cost-effectiveness, and cost-utility as well as meta-analysis can be comparatively pursued. Blending measures of costs and outcomes puts in perspective the heterogeneity of clinical endpoints in keratoconjunctivitis sicca.


Assuntos
Suplementos Nutricionais , Ácidos Graxos Ômega-3/uso terapêutico , Ceratoconjuntivite Seca/tratamento farmacológico , Ensaios Clínicos como Assunto , Análise Custo-Benefício , Relação Dose-Resposta a Droga , Esquema de Medicação , Ácidos Graxos Ômega-3/administração & dosagem , Ácidos Graxos Ômega-3/efeitos adversos , Ácidos Graxos Ômega-3/economia , Humanos , Estudos Prospectivos , Projetos de Pesquisa/normas , Resultado do Tratamento
8.
N Engl J Med ; 378(18): 1681-1690, 2018 05 03.
Artigo em Inglês | MEDLINE | ID: mdl-29652551

RESUMO

BACKGROUND: Dry eye disease is a common chronic condition that is characterized by ocular discomfort and visual disturbances that decrease quality of life. Many clinicians recommend the use of supplements of n-3 fatty acids (often called omega-3 fatty acids) to relieve symptoms. METHODS: In a multicenter, double-blind clinical trial, we randomly assigned patients with moderate-to-severe dry eye disease to receive a daily oral dose of 3000 mg of fish-derived n-3 eicosapentaenoic and docosahexaenoic acids (active supplement group) or an olive oil placebo (placebo group). The primary outcome was the mean change from baseline in the score on the Ocular Surface Disease Index (OSDI; scores range from 0 to 100, with higher scores indicating greater symptom severity), which was based on the mean of scores obtained at 6 and 12 months. Secondary outcomes included mean changes per eye in the conjunctival staining score (ranging from 0 to 6) and the corneal staining score (ranging from 0 to 15), with higher scores indicating more severe damage to the ocular surface, as well as mean changes in the tear break-up time (seconds between a blink and gaps in the tear film) and the result on Schirmer's test (length of wetting of paper strips placed on the lower eyelid), with lower values indicating more severe signs. RESULTS: A total of 349 patients were assigned to the active supplement group and 186 to the placebo group; the primary analysis included 329 and 170 patients, respectively. The mean change in the OSDI score was not significantly different between the active supplement group and the placebo group (-13.9 points and -12.5 points, respectively; mean difference in change after imputation of missing data, -1.9 points; 95% confidence interval [CI], -5.0 to 1.1; P=0.21). This result was consistent across prespecified subgroups. There were no significant differences between the active supplement group and the placebo group in mean changes from baseline in the conjunctival staining score (mean difference in change, 0.0 points; 95% CI, -0.2 to 0.1), corneal staining score (0.1 point; 95% CI, -0.2 to 0.4), tear break-up time (0.2 seconds; 95% CI, -0.1 to 0.5), and result on Schirmer's test (0.0 mm; 95% CI, -0.8 to 0.9). At 12 months, the rate of adherence to treatment in the active supplement group was 85.2%, according to the level of n-3 fatty acids in red cells. Rates of adverse events were similar in the two trial groups. CONCLUSIONS: Among patients with dry eye disease, those who were randomly assigned to receive supplements containing 3000 mg of n-3 fatty acids for 12 months did not have significantly better outcomes than those who were assigned to receive placebo. (Funded by the National Eye Institute, National Institutes of Health; DREAM ClinicalTrials.gov number, NCT02128763 .).


Assuntos
Suplementos Nutricionais , Ácidos Docosa-Hexaenoicos/uso terapêutico , Ácido Eicosapentaenoico/uso terapêutico , Ceratoconjuntivite Seca/tratamento farmacológico , Administração Oral , Adulto , Idoso , Suplementos Nutricionais/efeitos adversos , Ácidos Docosa-Hexaenoicos/efeitos adversos , Método Duplo-Cego , Ácido Eicosapentaenoico/efeitos adversos , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Azeite de Oliva/efeitos adversos , Azeite de Oliva/uso terapêutico , Índice de Gravidade de Doença , Falha de Tratamento
9.
BMC Vet Res ; 12(1): 214, 2016 Sep 22.
Artigo em Inglês | MEDLINE | ID: mdl-27658509

RESUMO

BACKGROUND: Canine keratoconjunctivitis sicca (cKCS) is an inflammatory eye condition related to a deficiency in the tear aqueous fraction. Etiopathogenesis of such disease is substantially multifactorial, combining the individual genetic background with environmental factors that contribute to the process of immunological tolerance disruption and, as a consequence, to the emergence of autoimmunity disease. In this occurrence, it is of relevance the role of the physiological immune-dysregulation that results in immune-mediated processes at the basis of cKCS. Current therapies for this ocular disease rely on immunosuppressive treatments. Clinical response to treatment frequently varies from poor to good, depending on the clinical-pathological status of eyes at diagnosis and on individual response to therapy. In the light of the variability of clinical response to therapies, we evaluated the use of an anti-inflammatory/antioxidant nutraceutical diet with potential immune-modulating activity as a therapeutical adjuvant in cKCS pharmacological treatment. Such combination was administered to a cohort of dogs affected by cKCS in which the only immunosuppressive treatment resulted poorly responsive or ineffective in controlling the ocular symptoms. RESULTS: Fifty dogs of different breeds affected by immune-mediated cKCS were equally distributed and randomly assigned to receive either a standard diet (control, n = 25) or the nutraceutical diet (treatment group, n = 25) both combined with standard immunosuppressive therapy over a 60 days period. An overall significant improvement of all clinical parameters (tear production, conjunctival inflammation, corneal keratinization, corneal pigment density and mucus discharge) and the lack of food-related adverse reactions were observed in the treatment group (p < 0.0001). CONCLUSIONS: Our results showed that the association of traditional immune-suppressive therapy with the antioxidant/anti-inflammatory properties of the nutraceutical diet resulted in a significant amelioration of clinical signs and symptoms in cKCS. The beneficial effects, likely due to the presence of supplemented nutraceuticals in the diet, appeared to specifically reduce the immune-mediated ocular symptoms in those cKCS-affected dogs that were poorly responsive or unresponsive to classical immunosuppressive drugs. These data suggest that metabolic changes could affect the immune response orchestration in a model of immune-mediated ocular disease, as represented by cKCS.


Assuntos
Adjuvantes Imunológicos/uso terapêutico , Dieta/veterinária , Suplementos Nutricionais , Doenças do Cão/terapia , Ceratoconjuntivite Seca/veterinária , Animais , Túnica Conjuntiva/patologia , Doenças do Cão/tratamento farmacológico , Cães , Imunossupressores/uso terapêutico , Ceratoconjuntivite Seca/tratamento farmacológico , Ceratoconjuntivite Seca/terapia , Resultado do Tratamento
10.
Arq Bras Oftalmol ; 78(5): 295-9, 2015.
Artigo em Inglês | MEDLINE | ID: mdl-26466228

RESUMO

PURPOSE: To evaluate the effectiveness of topical 1% cyclosporine eye drops diluted in either of the two vehicles-olive and linseed oil-and that of the oils themselves in treating experimentally-induced keratoconjunctivitis sicca (KCS) in rabbits. METHODS: KCS was induced in 25 New Zealand rabbits using 1% atropine sulfate eye drops for 7 days before treatment and throughout the treatment period (12 weeks). The rabbits were divided into five groups: one control (C) group without KCS induction and four treatment groups in which KCS was induced and treated topically with olive oil (O), linseed oil (L), cyclosporine in olive oil (CO), and cyclosporine in linseed oil (CL). The animals were evaluated using Schirmer tear test 1 (STT), the fluorescein test (FT), tear-film break-up time (TBUT), the rose bengal test (RBT), and histopathological analysis. RESULTS: Values of STT and TBUT significantly decreased 1 week post-induction (p<0.05) and were similar to initial values after the 4th week of treatment, in all groups. After KCS induction, there was significantly less corneal damage in group L than in group CL, as assessed FT and RBT. Histopathology demonstrated that Groups L and CL presented less edema and corneal congestion. There was no significant difference in the goblet cell density (cells/mm2) between the groups (p=0.147). CONCLUSION: Cyclosporine diluted in olive oil or linseed oil was effective in the treatment of KCS, although it had better efficacy when diluted in linseed oil. Linseed oil presented better effectiveness, whether associated or not, than olive oil. These results may contribute to the creation of novel topical ophthalmic formulations for KCS treatment in future.


Assuntos
Ciclosporina/administração & dosagem , Imunossupressores/administração & dosagem , Ceratoconjuntivite Seca/tratamento farmacológico , Óleo de Semente do Linho/administração & dosagem , Azeite de Oliva/administração & dosagem , Soluções Oftálmicas/administração & dosagem , Administração Oftálmica , Animais , Túnica Conjuntiva/efeitos dos fármacos , Túnica Conjuntiva/patologia , Córnea/efeitos dos fármacos , Córnea/patologia , Ciclosporina/química , Portadores de Fármacos/administração & dosagem , Combinação de Medicamentos , Fluoresceína , Células Caliciformes/efeitos dos fármacos , Imunossupressores/química , Ceratoconjuntivite Seca/patologia , Masculino , Soluções Oftálmicas/química , Coelhos , Reprodutibilidade dos Testes , Lágrimas/metabolismo , Resultado do Tratamento
11.
Arq. bras. oftalmol ; 78(5): 295-299, Sep.-Oct. 2015. ilus
Artigo em Inglês | LILACS | ID: lil-761518

RESUMO

ABSTRACTPurpose:To evaluate the effectiveness of topical 1% cyclosporine eye drops diluted in either of the two vehicles-olive and linseed oil-and that of the oils themselves in treating experimentally-induced keratoconjunctivitis sicca (KCS) in rabbits.Methods:KCS was induced in 25 New Zealand rabbits using 1% atropine sulfate eye drops for 7 days before treatment and throughout the treatment period (12 weeks). The rabbits were divided into five groups: one control (C) group without KCS induction and four treatment groups in which KCS was induced and treated topically with olive oil (O), linseed oil (L), cyclosporine in olive oil (CO), and cyclosporine in linseed oil (CL). The animals were evaluated using Schirmer tear test 1 (STT), the fluorescein test (FT), tear-film break-up time (TBUT), the rose bengal test (RBT), and histopathological analysis.Results:Values of STT and TBUT significantly decreased 1 week post-induction (p<0.05) and were similar to initial values after the 4th week of treatment, in all groups. After KCS induction, there was significantly less corneal damage in group L than in group CL, as assessed FT and RBT. Histopathology demonstrated that Groups L and CL presented less edema and corneal congestion. There was no significant difference in the goblet cell density (cells/mm2) between the groups (p=0.147).Conclusion:Cyclosporine diluted in olive oil or linseed oil was effective in the treatment of KCS, although it had better efficacy when diluted in linseed oil. Linseed oil presented better effectiveness, whether associated or not, than olive oil. These results may contribute to the creation of novel topical ophthalmic formulations for KCS treatment in future.


RESUMOObjetivo:Avaliar a eficácia do uso tópico do colírio de ciclosporina 1% em dois veículos, óleo de oliva e linhaça, e dos óleos separados, no tratamento da ceratoconjuntivite seca experimentalmente induzida (KCS) em coelhos.Método:Vinte e cinco coelhos Nova Zelândia foram induzidos para KCS com colírio de sulfato de atropina a 1% por sete dias antes e durante o período de tratamento (12 semanas) e foram divididos em 5 grupos, um grupo controle (C), sem indução de KCS e quatro grupos de tratamento tópico com ciclosporina em óleo de oliva (CO), ciclosporina em óleo de linhaça (CL), óleo de oliva (O) e óleo de linhaça (L). Os animais foram avaliados utilizando o teste lacrimal de Schirmer I (STT), teste de fluoresceína (FT), teste de ruptura do filme lacrimal (TBUT), teste de rosa bengala (RBT) e análise histopatológica.Resultados:Os valores de TBUT e STT diminuíram significativamente uma semana pós-indução da KCS (p<0,05) e foram semelhantes aos valores iniciais após a quarta semana de tratamento, em todos os grupos. Após a indução de KCS, houve menor dano na córnea no grupo L em relação ao grupo CL, quando avaliados FT e RBT. A histopatologia demonstrou que os grupos L e CL apresentaram menos edema e congestão da córnea. Não houve diferença significativa na densidade das células caliciformes (células/mm2) entre os grupos (p=0,147).Conclusão:Ciclosporina diluída em óleo de oliva ou linhaça foi eficiente no tratamento da CCS, porém teve uma melhor eficácia quando diluída no óleo de linhaça. O óleo de linhaça, isoladamente ou associado, apresentou melhor eficácia quando comparado ao óleo de oliva. Estes resultados podem contribuir no futuro com novas formulações oftálmicas tópicas no tratamento da CCS.


Assuntos
Animais , Masculino , Coelhos , Ciclosporina/administração & dosagem , Imunossupressores/administração & dosagem , Ceratoconjuntivite Seca/tratamento farmacológico , Óleo de Semente do Linho/administração & dosagem , Azeite de Oliva/administração & dosagem , Soluções Oftálmicas/administração & dosagem , Administração Oftálmica , Túnica Conjuntiva/efeitos dos fármacos , Túnica Conjuntiva/patologia , Córnea/efeitos dos fármacos , Córnea/patologia , Ciclosporina/química , Combinação de Medicamentos , Portadores de Fármacos/administração & dosagem , Fluoresceína , Células Caliciformes/efeitos dos fármacos , Imunossupressores/química , Ceratoconjuntivite Seca/patologia , Soluções Oftálmicas/química , Reprodutibilidade dos Testes , Resultado do Tratamento , Lágrimas
12.
Cornea ; 34(6): 644-50, 2015 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-25909234

RESUMO

PURPOSE: To evaluate the efficacy and safety of topical diquafosol ophthalmic solution for treatment of dry eye. METHODS: Randomized clinical trials (RCTs) from MEDLINE, EMBASE, and Cochrane Central Register of Controlled Trials (CENTRAL) were identified to evaluate the efficacy and safety of topical administration of diquafosol to patients with dry eyes. Data evaluation was based on endpoints including Schirmer test, tear film break-up time, ocular surface staining score, subjective symptom score, and adverse events. RESULTS: A total of 8 RCTs involving 1516 patients were selected based on the prespecified criteria. Significant improvement of Schirmer test values and tear film break-up time were reported in 40% (2 of 5) and 80% (4 of 5) studies, respectively. Ocular surface staining scores significantly decreased in 100% (fluorescein corneal staining, 6 of 6; Rose Bengal corneal and conjunctival staining, 4 of 4) RCTs. Symptoms significantly improved in 75% (6 of 8) RCTs in patients with dry eyes. No severe adverse events were reported with the concentration of diquafosol from 0.5% to 5%. Heterogeneity in study design prevented meta-analysis from statistical integration and summarization. CONCLUSIONS: Topical diquafosol seems to be a safe therapeutic option for the treatment of dry eye. The high variability of the selected RCTs compromised the strength of evidence and limits the determination of efficacy. However, the topical administration of diquafosol seems to be beneficial in improving the integrity of the epithelial cell layer of the ocular surface and mucin secretion in patients with dry eyes. This review indicates a need for standardized criteria and methods for evaluation to assess the efficacy of diquafosol in the future clinical trials.


Assuntos
Ceratoconjuntivite Seca/tratamento farmacológico , Polifosfatos/administração & dosagem , Agonistas do Receptor Purinérgico P2Y/administração & dosagem , Nucleotídeos de Uracila/administração & dosagem , Administração Tópica , Adulto , Idoso , Feminino , Fluoresceína , Corantes Fluorescentes , Humanos , Masculino , Pessoa de Meia-Idade , Soluções Oftálmicas , Polifosfatos/efeitos adversos , Agonistas do Receptor Purinérgico P2Y/efeitos adversos , Ensaios Clínicos Controlados Aleatórios como Assunto , Rosa Bengala , Lágrimas/química , Resultado do Tratamento , Nucleotídeos de Uracila/efeitos adversos
13.
Cornea ; 32(10): 1297-304, 2013 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-23884332

RESUMO

PURPOSE: Supplementation with gamma-linolenic acid (GLA) and omega-3 (n-3) polyunsaturated fatty acids (PUFAs) has been found to decrease the production of disease-relevant inflammatory mediators that are implicated in the pathogenesis of chronic dry eye. This study evaluated the effect of a supplement containing both GLA and n-3 PUFAs on signs and symptoms of moderate-to-severe keratoconjunctivitis sicca in postmenopausal patients. METHODS: This multicenter, double-masked placebo-controlled clinical trial enrolled 38 patients (both eyes) with tear dysfunction who were randomized to supplemental GLA + n-3 PUFAs or placebo for 6 months. Disease parameters, including Ocular Surface Disease Index, Schirmer test, tear breakup time, conjunctival fluorescein and lissamine green staining, and topographic corneal smoothness indexes (surface asymmetry index and surface regularity index), were assessed at baseline and at 4, 12, and 24 weeks. The intensity of dendritic cell CD11c integrin and HLA-DR expression was measured in conjunctival impression cytologies. RESULTS: The Ocular Surface Disease Index score improved with supplementation and was significantly lower than placebo (21 ± 4 vs. 34 ± 5) after 24 weeks (P = 0.05, n = 19 per group). The surface asymmetry index was significantly lower in supplement-treated subjects (0.37 ± 0.03, n = 15) than placebo (0.51 ± 0.03, n = 16) at 24 weeks (P = 0.005). Placebo treatment also significantly increased HLA-DR intensity by 36% ± 9% and CD11c by 34% ± 7% when compared with supplement treatment (n = 19 per group, P = 0.001, 24 weeks). Neither treatment had any effect on tear production, tear breakup time, or corneal or conjunctival staining. CONCLUSIONS: Supplemental GLA and n-3 PUFAs for 6 months improved ocular irritation symptoms, maintained corneal surface smoothness, and inhibited conjunctival dendritic cell maturation in patients with postmenopausal keratoconjunctivitis sicca.Clinical Trial Registration-URL: http://www.clinicaltrials.gov. Unique identifier: NCT00883649.


Assuntos
Ácidos Graxos Ômega-3/uso terapêutico , Ceratoconjuntivite Seca/tratamento farmacológico , Ácido gama-Linolênico/uso terapêutico , Adulto , Idoso , Idoso de 80 Anos ou mais , Antígeno CD11c/metabolismo , Túnica Conjuntiva/fisiologia , Topografia da Córnea , Método Duplo-Cego , Ácidos Graxos Ômega-3/efeitos adversos , Feminino , Fluoresceína/química , Antígenos HLA-DR/metabolismo , Humanos , Ceratoconjuntivite Seca/metabolismo , Corantes Verde de Lissamina/química , Masculino , Pessoa de Meia-Idade , Soluções Oftálmicas , Cooperação do Paciente , Coloração e Rotulagem/métodos , Lágrimas/fisiologia , Acuidade Visual/fisiologia , Ácido gama-Linolênico/efeitos adversos
14.
Am J Manag Care ; 17 Suppl 16: S432-9, 2011 12.
Artigo em Inglês | MEDLINE | ID: mdl-22435675

RESUMO

Dry eye disease (DED) is a multifactorial disorder that results in eye discomfort, visual disturbance, and often ocular surface damage. This supplement to The American Journal of Managed Care discusses the prevalence of DED and the economic burden associated with DED. The etiology and pathophysiology of DED will also be discussed, including disease progression and impact on the patient's quality of life. With greater understanding of the pathophysiology of DED, there are numerous available therapies/strategies for the management of the disorder, ranging from artificial tear substitutes, anti-inflammatory agents, secretagogues, punctal plugs, and systemic immunosuppressives, to surgery. This activity will aim to provide managed healthcare professionals with an understanding of when and how to use these different strategies to reduce morbidity and prevent complications.


Assuntos
Olho/fisiopatologia , Ceratoconjuntivite Seca/tratamento farmacológico , Ceratoconjuntivite Seca/fisiopatologia , Programas de Assistência Gerenciada , Soluções Oftálmicas/uso terapêutico , Corticosteroides/uso terapêutico , Envelhecimento/fisiologia , Ensaios Clínicos como Assunto , Ciclosporina/uso terapêutico , Suplementos Nutricionais , Ácidos Graxos Essenciais/uso terapêutico , Humanos , Imunossupressores/uso terapêutico , Ceratoconjuntivite Seca/diagnóstico , Ceratoconjuntivite Seca/epidemiologia , Guias de Prática Clínica como Assunto , Qualidade de Vida
15.
Graefes Arch Clin Exp Ophthalmol ; 248(11): 1639-46, 2010 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-20496151

RESUMO

BACKGROUND: Environmental oxidative stress changing the properties of the tear fluid can lead to keratoconjunctivitis sicca (dry eye syndrome). The aim of this study was to determine whether iodide iontophoresis influences the antioxidative capacity (ACW = water soluble antioxidative capacity) of the tear fluid, and to compare iodide iontophoresis with other balneotherapeutic measures. METHODS: This prospective study evaluated 92 patients in four groups. Twenty-four patients were treated with iodide iontophoresis, 24 with other balneotherapeutic methods. Twenty-five patients received iodide iontophoresis combined with other balneotherapeutic methods and 21 persons received no treatment (control). Unstimulated tear fluid, serum and urine were collected. ACW was determined photochemically in tear fluid and serum; iodine was measured in urine photometrically. RESULTS: Iodide iontophoresis increases the ACW of the tear fluid but not the ACW of the serum. Other iodine therapies increase the ACW in serum but not in tear fluid. Iodine excretion in urine was increased in all treated groups compared to the control. CONCLUSION: The increase of ACW in tear fluid after iodide iontophoresis can support the defense mechanism of the eye against oxidative influence effects, which may alleviate the symptoms of keratoconjunctivitis sicca.


Assuntos
Antioxidantes/metabolismo , Balneologia , Iontoforese/métodos , Ceratoconjuntivite Seca/tratamento farmacológico , Iodeto de Sódio/administração & dosagem , Lágrimas/metabolismo , Humanos , Ceratoconjuntivite Seca/metabolismo , Estresse Oxidativo , Estudos Prospectivos
16.
Arq Bras Oftalmol ; 70(4): 649-55, 2007.
Artigo em Português | MEDLINE | ID: mdl-17906762

RESUMO

PURPOSE: To evaluate if oral flaxseed oil (Linum usitatissimum), which reduces the inflammation in rheumatoid arthritis, may help keratoconjunctivitis sicca's treatment in Sjögren's syndrome patients. METHODS: In a randomized clinical trial, 38 female patients with rheumatoid arthritis or systemic lupus erithematosus associated with keratoconjunctivitis sicca and Sjögren's syndrome were consecutively selected from patients of the Department of Rheumatology of the Amazonas University Hospital. Keratoconjunctivitis sicca diagnosis was based on a dry-eye symptom survey score (Ocular Surface Disease Index - OSDI), Schirmer-I test, fluorescein break-up time, 1% Rose Bengal staining of ocular surface measured by the van Bijsterveld scale. All patients had ocular surface inflammation evaluated and quantified by conjunctival impression cytology, before and after the study. The subjects were divided into three groups with 13 (Group I), 12 (Group II) and 13 (Group III) patients. Group I received flaxseed oil capsules with a final 1 g/day dosis, Group II flaxseed oil capsules with a final 2 g/day dosis and Group III - controls - placebo, for 180 days. RESULTS: Comparing the results at the beginning and at the end of the treatment, statistically significant changes (p<0.05) in symptoms (OSDI), ocular surface inflammation quantified by conjunctival impression cytology, Schirmer-I test and fluorescein break-up time occurred in Groups I e II when compared to controls. CONCLUSIONS: Therapy with oral flaxseed oil capsules 1 or 2 g/day reduces ocular surface inflammation and ameliorates the symptoms of keratoconjunctivitis sicca in Sjögren's syndrome patients. Long-term studies are needed to confirm the role of this therapy for keratoconjunctivitis sicca in Sjögren's syndrome.


Assuntos
Ceratoconjuntivite Seca/tratamento farmacológico , Óleo de Semente do Linho/uso terapêutico , Síndrome de Sjogren/complicações , Administração Oral , Adulto , Artrite Reumatoide/complicações , Artrite Reumatoide/tratamento farmacológico , Técnicas de Diagnóstico Oftalmológico , Métodos Epidemiológicos , Feminino , Fluoresceína , Humanos , Ceratoconjuntivite Seca/diagnóstico , Óleo de Semente do Linho/administração & dosagem , Lúpus Eritematoso Sistêmico/complicações , Lúpus Eritematoso Sistêmico/tratamento farmacológico , Pessoa de Meia-Idade , Placebos , Rosa Bengala , Lágrimas/fisiologia
17.
Arq. bras. oftalmol ; 70(4): 649-655, jul.-ago. 2007. ilus, graf, tab
Artigo em Português | LILACS | ID: lil-461955

RESUMO

OBJETIVO: Avaliar se a utilização por via oral do óleo de linhaça (Linum usitatissimum), que diminui a inflamação na artrite reumatóide, pode auxiliar no tratamento da ceratoconjuntivite seca de portadores da síndrome de Sjõgren. MÉTODOS: Em estudo clínico randomizado, 38 pacientes do sexo feminino, com diagnóstico de artrite reumatóide ou lúpus eritematoso sistêmico associadas à ceratoconjuntivite seca e síndrome de Sjõgren, provenientes do ambulatório de Reumatologia do Hospital Universitário da Universidade Federal do Amazonas, foram consecutivamente selecionadas. O diagnóstico de ceratoconjuntivite seca foi baseado em questionário para olho seco (Ocular Surface Disease Index - OSDI®), Teste I de Schirmer, tempo de quebra do filme lacrimal com fluoresceína e instilação do corante rosa bengala a 1 por cento, com intensidade da impregnação da superfíce ocular quantificada pela escala de van Bijsterveld. Todas as pacientes tiveram a inflamação da superfície conjuntival avaliada e quantificada por interpretação de exame de citologia de impressão conjuntival antes do início e ao final do estudo. As pacientes foram divididas em três grupos: Grupo I (n=13), Grupo II (n=12) e Grupo III (n=13). O Grupo I recebeu cápsulas com dose final de 1 g/dia de óleo de linhaça, o Grupo II recebeu cápsulas com dose final de 2 g/dia de óleo de linhaça e o Grupo III - controle - recebeu cápsulas com placebo, por 180 dias. RESULTADOS: Comparando os resultados no início e no final do tratamento, foram verificadas mudanças estatisticamente significantes (p<0,05) nos sintomas medidos pelo OSDI®, na inflamação da superfície ocular quantificada pela citologia de impressão conjuntival e nos testes I de Schirmer e tempo de quebra do filme lacrimal com fluoresceína nos Grupos I e II, quando comparados ao Grupo-controle. CONCLUSÃO: Terapia oral com óleo de linhaça, em cápsulas na dose de 1 ou 2 g/dia, reduz a inflamação da superfície ocular e melhora os sintomas de...


PURPOSE: To evaluate if oral flaxseed oil (Linum usitatissimum), which reduces the inflammation in rheumatoid arthritis, may help keratoconjunctivitis sicca's treatment in Sjõgren's syndrome patients. METHODS: In a randomized clinical trial, 38 female patients with rheumatoid arthritis or systemic lupus erithematosus associated with keratoconjunctivitis sicca and Sjõgren's syndrome were consecutively selected from patients of the Departament of Reumatology of the Amazonas University Hospital. Keratoconjunctivitis sicca diagnosis was based on a dry-eye symptom survey score (Ocular Surface Disease Index - OSDI®), Schirmer-I test, fluorescein break-up time, 1 percent Rose Bengal staining of ocular surface measured by the van Bijsterveld scale. All patients had ocular surface inflammation evaluated and quantified by conjunctival impression cytology, before and after the study. The subjects were divided into three groups with 13 (Group I), 12 (Group II) and 13 (Group III) patients. Group I received flaxseed oil capsules with a final 1 g/day dosis, Group II flaxseed oil capsules with a final 2 g/day dosis and Group III - controls - placebo, for 180 days. RESULTS: Comparing the results at the beginning and at the end of the treatment, statistically significant changes (p<0.05) in symptoms (OSDI®), ocular surface inflammation quantified by conjunctival impression cytology, Schirmer-I test and fluorescein break-up time occurred in Groups I e II when compared to controls. CONCLUSIONS: Therapy with oral flaxseed oil capsules 1 or 2 g/day reduces ocular surface inflammation and ameliorates the symptoms of keratoconjunctivitis sicca in Sjõgren's syndrome patients. Long-term studies are needed to confirm the role of this therapy for keratoconjunctivitis sicca in Sjõgren's syndrome.


Assuntos
Adulto , Feminino , Humanos , Pessoa de Meia-Idade , Ceratoconjuntivite Seca/tratamento farmacológico , Óleo de Semente do Linho/uso terapêutico , Síndrome de Sjogren/complicações , Administração Oral , Artrite Reumatoide/complicações , Artrite Reumatoide/tratamento farmacológico , Técnicas de Diagnóstico Oftalmológico , Métodos Epidemiológicos , Fluoresceína , Ceratoconjuntivite Seca/diagnóstico , Óleo de Semente do Linho/administração & dosagem , Lúpus Eritematoso Sistêmico/complicações , Lúpus Eritematoso Sistêmico/tratamento farmacológico , Placebos , Rosa Bengala , Lágrimas/fisiologia
18.
Vet Clin North Am Small Anim Pract ; 34(3): 725-37, 2004 May.
Artigo em Inglês | MEDLINE | ID: mdl-15110981

RESUMO

Inflammation involves a universally recognized, although incompletely understood, cascade of molecular events orchestrated by lymphokines and other innate biochemicals of immunity. Repeated or extended contact with immunogenic agents results in adaptive immunity involving antigen-induced events that stimulate down-stream immune cells and result in expansion of the inflammatory cascade. When immunogenic stimulation persists or autoregulatory immune mechanisms go awry, however, adaptive immunologic events can result in immune-mediated processes detrimental to systemic or organ-specific homeostasis. Because of the complexities of immunologic events, the potential side effects of long-term corticosteroid therapy, and the focused spectrum of most conventional nonsteroidal anti-inflammatory agents (centered on arachidonic acid-related mechanisms), a variety of other chemotherapeutic immunosuppressive agents have assumed an increasingly prominent therapeutic role in veterinary ophthalmology in the management of chronic ocular inflammatory diseases. In addition, nonimmunosuppressive immunomodulating agents (ie, immuno-stimulants or immunorestoratives) may be used as adjunctive therapies in the management of ocular or visual system diseases.


Assuntos
Adjuvantes Imunológicos/administração & dosagem , Oftalmopatias/veterinária , Administração Tópica , Animais , Animais Domésticos , Oftalmopatias/tratamento farmacológico , Ceratoconjuntivite Seca/tratamento farmacológico , Ceratoconjuntivite Seca/veterinária , Soluções Oftálmicas/administração & dosagem
19.
J Ocul Pharmacol Ther ; 14(6): 497-504, 1998 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-9867333

RESUMO

The purpose of this study was to evaluate the efficacy of LO2A, a newly developed tear substitute containing glycerine and sodium hyaluronate, in the treatment of dry eyes. Twenty-five informed consent patients suffering from keratoconjunctivitis sicca were included. Patients were treated for one week with LO2A in one eye, and with their current tear substitute in the other eye. Rose bengal staining was evaluated on a scale of 0 to 3. Patient satisfaction was graded on a scale of 1 to 5. The average satisfaction score for LO2A was significantly higher compared to the control preparations at 1 week (p=0.0003) and at 2 weeks (p=0.0232). A highly significant reduction in rose bengal staining was demonstrated following 1 week of treatment with LO2A (p<0.0001). The LO2A treated eyes had significantly less staining than control eyes at 1 week (p=0.021) and at 2 weeks (p=0.023). An inverse correlation was found between patient grading and the rose bengal scoring (spearman rank coefficient = -0.49, p<0.001). LO2A showed a beneficiary effect on dry eye patient satisfaction and on rose bengal test, as compared to other tear substitute preparations currently used by these patients.


Assuntos
Glicerol/uso terapêutico , Ácido Hialurônico/uso terapêutico , Ceratoconjuntivite Seca/tratamento farmacológico , Soluções Oftálmicas/uso terapêutico , Avaliação de Medicamentos , Humanos , Ceratoconjuntivite Seca/fisiopatologia , Satisfação do Paciente , Rosa Bengala , Lágrimas/fisiologia
20.
Acta Ophthalmol (Copenh) ; 72(4): 438-42, 1994 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-7825408

RESUMO

Topical cyclosporin 2% in olive oil was investigated for its possible immunoregulatory role on the dry eye state in patients with secondary Sjögren's syndrome. The study was a randomized, double-masked, placebo-controlled trial. Thirty eyes of 15 patients were randomized to undergo treatment with topical cyclosporin in olive oil and 30 eyes of the other 15 patients received a placebo, which was the sterile olive oil used as a vehicle for the cyclosporin. The effect of the 2-month long treatment with either medication on the status of the dry eye state was measured by Schirmer-I test, tear film break-up time and rose bengal staining. There was a significant increase in the break-up time and a significant decrease in rose bengal staining score between the cyclosporin and control groups at the end of the 2-month study period (p < 0.01). Schirmer-I test remained unaffected (p > 0.05). These results probably indicate that topical cyclosporin modulates the goblet cell function in secondary Sjögren's associated keratoconjunctivitis sicca and through this mucus enhancing action or some other mechanism not yet known, helps to maintain the structural integrity of the epithelium.


Assuntos
Ciclosporina/uso terapêutico , Ceratoconjuntivite Seca/tratamento farmacológico , Síndrome de Sjogren/etiologia , Administração Tópica , Ciclosporina/administração & dosagem , Método Duplo-Cego , Epitélio/efeitos dos fármacos , Feminino , Humanos , Ceratoconjuntivite Seca/complicações , Aparelho Lacrimal/efeitos dos fármacos , Masculino , Pessoa de Meia-Idade , Soluções Oftálmicas , Rosa Bengala , Lágrimas/química , Lágrimas/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA